Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Replaces CEO, Plans to Spin Out Vilazodone Business

NEW YORK, May 15 (GenomeWeb News) - Clinical Data's board has approved plans to spin out the firm's investigational antidepressant drug vilazodone into a new company.


Clinical Data also said President and CEO Israel Stein has stepped down to become executive vice chairman. He will also serve as interim CFO, replacing Mark Shooman. Drew Fromkin, previously executive vice president of Clinical Data and president of the company's PGxHealth division, will now serve as president and CEO.


Clinical Data said it will spin out the vilazodone business to shareholders as a new company called Precigen Therapeutics. The new firm will develop the drug, as well as a potential companion biomarker test that will be developed by Clinical Data's PGxHealth division.


Clinical Data said it plans to issue the new company's shares to Clinical Data shareholders in the form of a tax-free stock dividend.


News of the spin out comes about two months after Clinical Data reorganized itself into three units: PGxHealth, Cogenics, and Vital Diagnostics.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.